Amid all the debate, we’ve neglected to update the ReadMeFirst packet. The ECCO PR and webcast notes ought to be added, and some of the old posts about Monte Carlo simulations can be removed as they are now immaterial. The last RMF update was more than a month ago, so there may be other items worthy of inclusion. T.i.a. Dew
The DNDN ReadMeFirst is more than six weeks old and doesn’t contain any of the info from ECCO. Are you planning to update it?
If so, I think you can clean it up by deleting the old posts with Monte Carlo simulation runs by such people as double_pedro and ocyanblue. (Now that the actual data are out, who cares about these simulations?)
If you don’t update the RMF fairly soon, I’ll probably do it myself, and I’ll probably include PGS’s seminal “scam” post. So there’s your incentive :-)
Updated with three most recent webcasts (10/31 conf call on Provenge 9902A trial results at ECCO, 11/4 conf call on Q3 financial results, 11/7 webcast at Rodman & Renshaw conference) http://investor.dendreon.com/medialist.cfm
9901 trial Gleason score breakdown (we now know that 4 out of 5 surviving placebo arm patients crossed over to receive salvage Provenge after progression) http://tinyurl.com/5v6xy
Biotech Monthly has the most comprehensive background info for Dendreon, far more than any brokerage house. The Nov 2004 issue would be available for a single-issue purchase, approx 40 pages are devoted to Dendreon. Price for single issue is in the $100 range. The issue covers the Provenge mechanism of action, trial history, and pipeline. http://www.biotechMonthly.com/archive_2004.htm
Market Data 
Markets 
AI
